Drug
Gemcitabine clinical trials
Also written Gemzar, LY188011 and FF 10832.
Includes 2 studies of Gemcitabine Liposome FF-10832.
Related medicines add 5 studies
Counted the way a researcher would: Gemcitabine with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Gemcitabine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Gemcitabine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 15 May 1996 · GEMZAR · NDA 020509 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
1,359 studies that test it; most in 2006 (81); 3 more planned to start later
| Year | Studies |
|---|---|
| 1995 | 2 |
| 1996 | 1 |
| 1997 | 14 |
| 1998 | 27 |
| 1999 | 38 |
| 2000 | 35 |
| 2001 | 53 |
| 2002 | 49 |
| 2003 | 75 |
| 2004 | 73 |
| 2005 | 79 |
| 2006 | 81 |
| 2007 | 59 |
| 2008 | 54 |
| 2009 | 49 |
| 2010 | 35 |
| 2011 | 56 |
| 2012 | 47 |
| 2013 | 52 |
| 2014 | 39 |
| 2015 | 52 |
| 2016 | 43 |
| 2017 | 34 |
| 2018 | 48 |
| 2019 | 33 |
| 2020 | 28 |
| 2021 | 26 |
| 2022 | 22 |
| 2023 | 37 |
| 2024 | 47 |
| 2025 | 27 |
| 2026 | 44 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 220 · Other 1,157
Eli Lilly and Company (68) · National Cancer Institute (NCI) (49) · M.D. Anderson Cancer Center (42) · Memorial Sloan Kettering Cancer Center (35) · Alliance for Clinical Trials in Oncology (27) · SWOG Cancer Research Network (21) · Fudan University (19) · Sun Yat-sen University (16)
Often tested with
Tested in the same studies.
Cisplatin (321) · Paclitaxel (241) · Albumin-Bound Paclitaxel (159) · Docetaxel (122) · Oxaliplatin (118) · Carboplatin (115) · Capecitabine (76) · Bevacizumab (70)
Related medicines
As reviewed, each with the page that says it.
- One of Antimetabolites source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 85 phase 3 studies under way
Gemcitabine is the comparator. A study of two new drugs counts under both.
- 5Durvalumab · AstraZeneca · next primary completion Jul 2027
- 4Pembrolizumab · Astellas Pharma Global Development, Inc., Merck Sharp & Dohme LLC · next primary completion Mar 2030
- 4Sacituzumab govitecan · Gilead Sciences, National Cancer Institute (NCI) · next primary completion Dec 2026
- 4Oxaliplatin · CSPC Ouyi Pharmaceutical Co., Ltd., Fudan University · next primary completion Mar 2027
- 4Fluorouracil · Fudan University, Sun Yat-sen University · next primary completion Mar 2027
- 4Notiretatug rezetecan · Suzhou Suncadia Biopharmaceuticals Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd. · next primary completion Dec 2027
- 3Sacituzumab tirumotecan · Merck Sharp & Dohme LLC, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · next primary completion Dec 2026
- 3Rinatabart sesutecan · Genmab · next primary completion Sep 2027
Reaching primary completion within a year · 65, 7 in phase 3
Studies that test Gemcitabine, phase 3 first.
- Nov 2026A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)Phase 3 · Sichuan Baili Pharmaceutical Co., Ltd.
- Nov 2026Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine CancerPhase 3 · National Institute of Cancerología
- Dec 2026Paediatric Hepatic International Tumour TrialPhase 3 · University of Birmingham
- Dec 2026Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical CancerPhase 3 · Hospital do Coracao
- Apr 2027A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.Phase 3 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- May 2027A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic CancerPhase 3 · Akeso
- Sep 2027A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)Phase 2/3 · Merck Sharp & Dohme LLC
- Nov 2026Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder CancerPhase 2 · ImmunityBio, Inc.
- Dec 2026A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract CancerPhase 2 · AHS Cancer Control Alberta
- Dec 2026A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder CancerPhase 1/2 · Memorial Sloan Kettering Cancer Center
Studies
Open first, then newest update. How each study uses Gemcitabine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 1,377
- The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential TherapyRecruitingPhase 2National Cancer Center, KoreaNCT06388720Written as gemcitabine
- A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder CancerRecruitingPhase 3Ferring PharmaceuticalsNCT06545955Written as Gemcitabine
- Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard TreatmentRecruitingPhase 2City of Hope Medical CenterNCT07275216Written as Gemcitabine
- Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic CancerRecruitingPhase 2Loma Linda UniversityNCT03492671Written as Gemcitabine 1000 mg
- Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary MetastasesRecruitingPhase 1M.D. Anderson Cancer CenterNCT03093909Written as Gemcitabine
- Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)RecruitingPhase 2Sabine Mueller, MD, PhDNCT07447076Written as Gemcitabine
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal CancerRecruitingPhase 2National Cancer Institute (NCI)NCT06029270Written as Gemcitabine
- Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaRecruitingPhase 3Revolution Medicines, Inc.NCT07805954Written as gemcitabine
- A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinomaNot yet recruitingPhase 2Mehmet AkceNCT06855225Written as Gemcitabine
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)RecruitingPhase 2/3Merck Sharp & Dohme LLCNCT05139017Written as Gemcitabine
- Risk-Enabled Therapy After Initiating EV/Pembro for Bladder CancerRecruitingPhase 2Fox Chase Cancer CenterNCT07908979Written as Gemcitabine
- HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic CancerNot yet recruitingPhase 3Shanghai Hengrui Pharmaceutical Co., Ltd.NCT07900789Written as HRS -4642 + SHR-1316+ Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection
- Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLCRecruitingPhase 2Swiss Cancer InstituteNCT07158489Written as Gemcitabine + Ivonescimab
- Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System LymphomaNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07888621Written as Gemcitabine
- ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin LymphomaRecruitingPhase 2Michael Spinner, MDNCT07021989Written as Gemcitabine
- Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell LymphomasRecruitingPhase 2National Research Center for Hematology, RussiaNCT07883135Written as Gemcitabine & oxaliplatin
- A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitabine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer Cle-InvasiveNot yet recruitingPhase 4AstraZenecaNCT07876817Written as Gemcitabine
- Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar CholangiocarcinomaRecruitingPhase 2Jinbo YueNCT07030140Written as Gemcitabine
- A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)RecruitingPhase 2National Cancer Institute (NCI)NCT06064097Written as Gemcitabine
- In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE TrialRecruitingPhase 1/2Mayo ClinicNCT06704191Written as Gemcitabine
See all 1,377 studies that test Gemcitabine →
Given beside what is tested · 931 — Gemcitabine is usual care or a partner of the new treatment
- A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal CancerRecruitingPhase 1Astellas Pharma Global Development, Inc.NCT07024615Written as Gemcitabine
- CR-001 in Adult Participants With Locally Advanced or Metastatic Solid TumorsRecruitingPhase 1/2Crescent Biopharma, Inc.NCT07335497Written as Gemcitabin
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerRecruitingPhase 2National Cancer Institute (NCI)NCT03606967Written as Gemcitabine Hydrochloride
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract CancerRecruitingPhase 2/3National Cancer Institute (NCI)NCT04628767Written as Gemcitabine Hydrochloride
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])RecruitingPhase 3National Cancer Institute (NCI)NCT04267848Written as Gemcitabine Hydrochloride
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ TrialRecruitingPhase 2National Cancer Institute (NCI)NCT03907475Written as Gemcitabine Hydrochloride
- Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin LymphomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT03618550Written as gemcitabine
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06312137Written as Gemcitabine
- Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHLRecruitingPhase 2Hoffmann-La RocheNCT06806033Written as Gemcitabine
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsRecruitingPhase 1/2Verastem, Inc.NCT07020221Written as Gemcitabine + Nab-paclitaxel
- A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06623422Written as Gemcitabine
- A Study of Azenosertib (ZN-c3) in Patients With Ovarian CancerRecruitingPhase 1K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT04516447Written as Gemcitabine
- ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerRecruitingPhase 2ALX Oncology Inc.NCT07007559Written as Gemcitabine
- GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Metastatic PDACRecruitingPhase 1/2West China HospitalNCT07802184Written as gemcitabine
- Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)RecruitingPhase 1/2Inhibrx Biosciences, IncNCT04198766Written as Gemcitabine (1000 mg/m2)
- A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line TherapyRecruitingPhase 1/2Shenzhen Majory Biotechnology Co., Ltd.NCT07235202Written as Gemcitabine (GEM)
- Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )RecruitingPhase 3Revolution Medicines, Inc.NCT07621718Written as Gemcitabine (GEM)
- A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07829783Written as Gemcitabine
- A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)RecruitingPhase 2Merck Sharp & Dohme LLCNCT07793942Written as Gemcitabine
- MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract CarcinomaRecruitingPhase 2Centre Hospitalier Universitaire de BesanconNCT07036380Written as Gemcitabine + Cisplatin + Durvalumab
Showing 20 of 931.
As the comparator · 236 — what is tested is compared with Gemcitabine
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06843447Written as Gemcitabine
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerRecruitingPhase 3National Cancer Institute (NCI)NCT06524544Written as Gemcitabine
- Autologous Tumor Infiltrating Lymphocytes Injection (GT101 Injection) for the Treatment of Recurrent or Metastatic Cervical CancerRecruitingPhase 2Grit BiotechnologyNCT06241781Written as Gemcitabine injection
- Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)RecruitingPhase 2/3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06879145Written as Gemcitabine Hydrochloride for Injection
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06841354Written as Gemcitabine
- A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07743164Written as Gemcitabine
- BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based TherapyRecruitingPhase 3SystImmune Inc.NCT07869836Written as Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin)
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC TrialRecruitingPhase 2National Cancer Institute (NCI)NCT06770582Written as Gemcitabine
- Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPCRecruitingPhase 3First Affiliated Hospital of Guangxi Medical UniversityNCT07459296Written as Gemcitabine (GEM)
- Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance TherapyRecruitingPhase 2National Cancer Institute (NCI)NCT07504588Written as Gemcitabine
- Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingPhase 3Immuneering CorporationNCT07562152Written as GnP
- Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian CancerRecruitingPhase 3GenmabNCT07564141Written as Gemcitabine
- A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerRecruitingPhase 3Eli Lilly and CompanyNCT07213804Written as Gemcitabine
- A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder CancerRecruitingPhase 3Janssen Research & Development, LLCNCT06319820Written as Gemcitabine
- A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder CancerRecruitingPhase 3Janssen Research & Development, LLCNCT06919965Written as Gemcitabine
- An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in ChinaRecruitingPhase 3GenmabNCT07604766Written as Gemcitabine
- Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)RecruitingPhase 3Astellas Pharma Global Development, Inc.NCT07566156Written as Gemcitabine
- Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic CholangiocarcinomaNot yet recruitingPhase 3Zhejiang Cancer HospitalNCT07691515Written as Gemcitabine
- A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)RecruitingPhase 3GlaxoSmithKlineNCT07286266Written as Gemcitabine
- A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingPhase 3Shanghai Junshi Bioscience Co., Ltd.NCT07808827Written as JS203 in combination with gemcitabine and oxaliplatin
Showing 20 of 236.
What changed recently
From the registry's own updates since Oct 15, 2026.
Results posted3
- A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal CancerNov 4, 2026NCT03929666
- Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.Nov 4, 2026NCT04753879
- Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)Nov 3, 2026NCT06571708
Stopped1
- Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)TerminatedNov 3, 2026NCT06571708
Newly registered5
- Risk-Enabled Therapy After Initiating EV/Pembro for Bladder CancerNov 2, 2026NCT07908979
- HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic CancerOct 28, 2026NCT07900789
- Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System LymphomaOct 22, 2026NCT07888621
- Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell LymphomasOct 20, 2026NCT07883135
- A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitabine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer Cle-InvasiveOct 15, 2026NCT07876817
Codes
What other systems call Gemcitabine · ClinicalTrials.gg INT006865
- MeSH (NLM) D000093542GemcitabineConfirmed ClinicalTrials.gov, Wikidata
- UNII (FDA) B76N6SBZ8RGEMCITABINEConfirmed FDA, Wikidata
- RxNorm 12574Confirmed FDA, Wikidata
- Wikidata Q414143gemcitabineConfirmed FDA, Wikidata
- NCI Thesaurus C66876GemcitabineOne source FDA
- DrugBank DB00441One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000093542 | Gemcitabine | Confirmed ClinicalTrials.gov, Wikidata |
| UNII (FDA) | B76N6SBZ8R | GEMCITABINE | Confirmed FDA, Wikidata |
| RxNorm | 12574 | — | Confirmed FDA, Wikidata |
| Wikidata | Q414143 | gemcitabine | Confirmed FDA, Wikidata |
| NCI Thesaurus | C66876 | Gemcitabine | One source FDA |
| DrugBank | DB00441 | — | One source Wikidata |
Also registered as gemcitabine hydrochloride (UNII U347PV74IL · RxNorm 236234).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.